Chen YW, Ni L, Ospina-Forero L. Visualising internal migration flows across local authorities in England and Wales. EPA. 2021 Jun;53(4):616-8. doi: 10.1177/0308518X20968568
Chen YW, Ni L, Xu DL, Yang JB. Visualising regional disparities in the risk of COVID-19 at different phases of lockdown in England. EPA. 2021 Jan 19;53(5):883-6. doi: 10.1177%2F0308518X20984165
Wolowacz SE, Petrillo J, Doward LC, Briggs A. Measuring health-state utility values in clinical trials: can we do better? Ispor Connections. 2014 Sep;20(5):4-8.
Glück S, Russell C, O'Shaughnessy J, McKenna EF, Hu S, Odom D, Blum JL. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast. 2013 Dec;22(6):1087-93. doi: 10.1016/j.breast.2013.08.016.
Stull DE, Houghton KF, Petrillo J. Innovative data analysis for demonstrating product value: analysis of heterogeneity in treatment response in clinical trials. Ispor Connections. 2013;19(1):5-8.
Masters E, Zlateva G, Harris NI. Real-world data for use in the real world: the pain paradigm. Ispor Connections. 2013;19(2):9-11.
Brogan AJ, Deniz B, Miller JD, Mladsi DM, Herring WL, Thompson JR. Cost-effectiveness assessment of telaprevir combination therapy compared with pegylated interferon and ribavirin alone in the management of chronic hepatitis C virus infection in Canada. Poster presented at the 2012 Canadian Digestive Diseases Week and the Annual Winter Meeting of the Canadian Association for the Study of the Liver; February 24, 2012. Montreal, Canada. [abstract] Can J Gastroenterol. 2012 Feb; 26(Suppl(SA)).
Dine JL, Schneider MK, Stewart BR, Armer JM. Learning from traditional healers in South Africa. J Lymphoedema. 2009;4(2):10-6.
Wolowacz SE, Khan SB. The New National Institute of Health and Clinical Excellence (NICE) Single Technology Appraisal (STA) process: experience from the first completed appraisals. Ispor Connections. 2007;13(2):12-5.